Skip to main
OTLK
OTLK logo

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc. has demonstrated significant advancements in its product development, receiving marketing authorization in the European Union and United Kingdom for its monoclonal antibody ONS-5010, aimed at treating wet age-related macular degeneration. The company's recent clinical trial, NORSE EIGHT, has shown promising results, indicating noninferiority to existing treatments, while strategic collaborations, such as with Cencora, position the company for successful product launches and potentially increased market presence. Although G&A and R&D expenses have risen considerably year-over-year, this investment is essential for accelerating clinical progress and addressing unmet patient needs, contributing to a favorable long-term financial outlook.

Bears say

Outlook Therapeutics reported a significant loss per share of $0.78 for the first quarter of 2024, with operating losses escalating to $21.6 million, exceeding previous estimates and indicating deteriorating financial health. The company's failure to meet the pre-specified non-inferiority endpoint in the NORSE EIGHT clinical study raises concerns about its competitive positioning and may lead to further regulatory hurdles delaying product approval. Additionally, the adjustment of the enterprise value-to-sales multiple from 7.5x to 3.5x reflects a more pessimistic view on revenue generation prospects, exacerbating fears of potential share dilution from future equity financing.

OTLK has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 10 analysts, OTLK has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.